65 followers
RT @archbiopartners: 🫀 2018 global panel (https://t.co/3y1MPQR3br) defines the key drivers of CS-AKI: inflammation, ischemia, and toxins.…
RT @archbiopartners: 🫀 2018 global panel (https://t.co/3y1MPQR3br) defines the key drivers of CS-AKI: inflammation, ischemia, and toxins.…
🫀 2018 global panel (https://t.co/EhBHjHHKTw) defines the key drivers of CS-AKI: inflammation, ischemia, and toxins. These are the same targets of Arch Biopartners’ Phase II trials. 📖 Learn more: https://t.co/HhXKl6yH4q #CSAKI #AKI #TrialRationale #A…
RT @biomerieuxcmo: JAHA special report on Acute Kidney Injury (AKI) in Cardio-Vascular surgery. Inclusion of urine biomarkers like NephroCh…